Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- XRTX
- Price
- 0.87
- Stock movement up
- +0.08 (11.13%)
- Company name
- XORTX Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 4.17M
- Ent value
- 3.59M
- Price/Sales
- -
- Price/Book
- 1.95
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -29.82%
- 1 year return
- -44.05%
- 3 year return
- -60.75%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-09-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
XRTX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 1.95 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 5.21M |
| EPS (TTM) | -0.25 |
| FCF per share (TTM) | -1.44 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -109.55K |
| Operating income (TTM) | -6.86M |
| Net income (TTM) | -736.66K |
| EPS (TTM) | -0.25 |
| EPS (1y forward) | -1.22 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 2.30M |
| Net receivables | 13.11K |
| Total current assets | 2.41M |
| Goodwill | 0.00 |
| Intangible assets | 185.70K |
| Property, plant and equipment | 0.00 |
| Total assets | 3.85M |
| Accounts payable | 110.74K |
| Short/Current long term debt | 61.47K |
| Total current liabilities | 1.72M |
| Total liabilities | 1.72M |
| Shareholder's equity | 2.13M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -4.09M |
| Capital expenditures (TTM) | 44.68K |
| Free cash flow (TTM) | -4.17M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -34.53% |
| Return on Assets | -19.13% |
| Return on Invested Capital | -33.56% |
| Cash Return on Invested Capital | -190.04% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.71 |
| Daily high | 0.87 |
| Daily low | 0.70 |
| Daily Volume | 158K |
| All-time high | 60.39 |
| 1y analyst estimate | 14.47 |
| Beta | -0.03 |
| EPS (TTM) | -0.25 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| XRTX | S&P500 | |
| Current price drop from All-time high | -98.68% | -1.46% |
| Highest price drop | -98.81% | -56.47% |
| Date of highest drop | 20 Aug 2025 | 9 Mar 2009 |
| Avg drop from high | -77.61% | -10.99% |
| Avg time to new high | 88 days | 12 days |
| Max time to new high | 994 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
4.17M
Marketcap category
Small-cap
Description
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page